Abstract：OBJECTIVE: To study the relationship of GYPC and TRIP3 gene expression and the prognosis of acute lymphoblastic leukemia (ALL) in children in order to explore the molecular biological mechanisms of recurrence and remission of ALL. METHODS: Thirty-eight newly diagnosed ALL children were enrolled. Of the 38 patients, 31 achieved complete remission (CR) and 12 relapsed. Semi-quantitative RT-PCR was employed to measure blood GYPC and TRIP3 gene expression. Twenty blood samples from normal children were used as controls. RESULTS: Blood GYPC expression in newly diagnosed ALL children was significantly higher than that in the control group (P<0.01) and the CR group (P<0.01). The expression of GYPC gene in the CR group was similar to that in the control group. Other than the control group (P<0.01) and the CR group (P<0.01), the GYPC expression of the relapse group was significantly higher than that in the newly diagnosed group (P<0.01). The CR group showed lower GYPC gene expression than the non-remission group before treatment (P<0.05). Blood expression of TRIP3 gene in the newly diagnosed and the relapse groups was significantly lower than that in the control group (P<0.05). The CR group had increased TRIP3 gene expression compared with the control group (P<0.01) as well as the newly diagnosed and the relapse groups (P<0.01). Of the 38 newly diagnosed ALL children, the patients with positive TRIP3 expression showed higher remission rate than those with negative TRIP3 (P<0.05). The TRIP3 gene expression before treatment in patients who achieved CR was higher than that in non-remission patients (P<0.05). CONCLUSIONS: A high GYPC gene expression is associated with an unfavorable outcome, in contrast, a high TRIP3 gene expression is associated with a favorable outcome in childhood ALL.［Chin J Contemp Pediatr, 2009, 11 (1):29-32］
ZHANG Jian-Bai,LI Xiao-Hui,NING Fang et al. Relationship between expression of GYPC and TRIP3 genes and prognosis of acute lymphoblastic leukemia in children[J]. CJCP, 2009, 11(01): 29-32.
［1］Boyse J, Hewitt M, Mott MG. Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia［J］. Br J Haematol, 1996, 93(1):117-124.
［2］Villeval JL, Le Van Kim C, Bettaieb A. Early expression of glycophorin C during normal and leukemic human erythroid differentiation［J］. Cancer Res, 1989, 49(10):2626-2632.
［3］Lee JW, Choi HS, Gyuris J, Brent R, Moore DD. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor［J］. Mol Endocrinol, 1995, 9(2):243-254.
［5］Daniels G, King MJ, Avent ND, Khalid G, Reid M, Mallinson G, et al. A point mutation in the GYPC gene results in the expression of the blood group Ana antigen on glycophorin D but not on glycophorin C: further evidence that glycophorin D is a product of the GYPC gene［J］. Blood, 1993, 82(10):3198-3203.
［6］Robinson J, Seiff C, Delia D, Edwards PA, Greaves M. Expression of cell-surface HLA-DR, HLA-ABC and glycophorin during erythroid differentiation［J］. Nature, 1981, 289(5793):68-71.
［7］Greaves MF, Chan LC, Furly AJ, Watt SM, Molgaard HV. Lineage promiscuity in hemopoietic differentiation and leukemia［J］. Blood, 1986, 67(1):1-11.
［8］Marfatia SM, Leu RA, Branton D, Chishti AH. Identification of the protein 4.1 binding interface on glycophorin C and p55, a homologue of the Drosophila discs-large tumor suppressor protein［J］. J Biol Chem, 1995, 270(2):715-719.
［9］Lofthouse JT. Evidence for age-related deamidation reactions in erythrocyte p55 and glycophorins C and D: implications for signal transduction involving tumour-suppressor proteins in higher eukaryotes［J］. Med Hypotheses, 1998, 51(4):321-324.
